Clinical Trials Actively Recruiting in Canada

Breakdown for each trial:
• Name of trial
• Short summary
• Countries recruiting
• Link to trial page on
• Trial Status

PDSA Patient Consented Natural History Study Registry

This global ITP registry study is FDA approved and developed in partnership with the National Organization for Rare Disorders (NORD) to follow ITP patients of all ages, in all phases of disease to learn more about the natural history of ITP. The goal of the registry is to learn more about the clinical characteristics of ITP, the incidence of co-morbidities, treatment patterns, adverse outcomes, how quality of life is impacted, how family and socioeconomics is affected, and how ITP patients respond to COVID-19 and vaccinations.  Note: The registry is in English only, currently.

USA, Canada, International (all places).


Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Pfizer is conducting an interventional phase two, open-label, one-arm, multicenter study to determine the safety and efficacy of a drug, PF-06835375, in adults with moderate-severe bleeding due to ITP. Specifically, the study will determine if the drug can increase platelet counts to reduce bleeding risks, without a significant side effect profile. PF-06835375 is a chemokine (CXCR5) receptor antagonist that works as an immune system regulator and has been reported as a critical chemokine regulator in several autoimmune diseases. Its mechanism of action is not fully understood yet. The drug would be provided through a subcutaneous injection every month for a total of three months. Eligible participants include adults (between the ages of 18-70 years) with primary persistent or chronic ITP (over 3 months since diagnosis) who have a platelet count less than 50,000/μL and have not experienced severe bleeding within 1 month. Individuals who have had a splenectomy within three months of the study initiation period will be excluded from participating.

Australia, Canada, Czechia, Hungary, Poland, USA.

Status: Recruiting

Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia

This is a randomized double-blind pilot study to determine the clinical utility of using Oseltamirvir compared to placebo in the treatment of ITP. Oseltamivir is an attractive drug for ITP since it specifically targets a pathophysiologic mechanism that appears to be important for the development of ITP and has a benign side effect profile compared to standard ITP therapy. Eligibility includes adults with ITP who have not had a sustained response to other available treatments.


Status: Unknown

A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)

Principia Biopharma is conducting a study of their oral drug PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options and have a platelet count <30,000/μL on two counts no sooner than 7 days apart in the 15 days before treatment begins. Preclinical findings show that PRN1008 decreases the activity of B cells and other inflammatory-causing immune cells, and in a mouse model of ITP show that PRN1008 can reduce platelet loss.

USA, Australia, Bulgaria, Canada, Czech Republic, Netherlands, Norway, and United Kingdom


Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo